Abstract
Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Current Pharmaceutical Design
Title:Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach
Volume: 24 Issue: 1
Author(s): Adriana Trompetero, Aldemar Gordillo, Mora Carolina del Pilar, Velasquillo María Cristina and Rosa Helena Bustos Cruz*
Affiliation:
- Universidad de la Sabana, Faculty of Medicine, Therapeutic Evidence Group, Chía,Colombia
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Abstract: Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Export Options
About this article
Cite this article as:
Trompetero Adriana , Gordillo Aldemar, del Pilar Carolina Mora , Cristina María Velasquillo and Bustos Cruz Helena Rosa*, Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach, Current Pharmaceutical Design 2018; 24 (1) . https://dx.doi.org/10.2174/1381612823666170828133059
| DOI https://dx.doi.org/10.2174/1381612823666170828133059 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc., has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Accelerating Cancer drug discovery using Artificial intelligence and In Silico methods
The Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Pharmacogenomics in Psychiatry: Implications for Practice
Recent Patents on Biotechnology Role of Astrocytes, Soluble Factors, Cells Adhesion Molecules and Neurotrophins in Functional Synapse Formation: Implications for Human Embryonic Stem Cell Derived Neurons
Current Stem Cell Research & Therapy Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Monoamine Oxidase B Inhibitors in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Improvement of Microscopic MR Imaging of Amyloid Plaques with Targeting and Non-Targeting Contrast Agents
Current Medical Imaging Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design miRNAs in Alzheimer Disease – A Therapeutic Perspective
Current Alzheimer Research Astrocytes and Inflammasome: A Possible Crosstalk in Neurological Diseases
Current Medicinal Chemistry Commentary: Olfactory Dysfunction in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets X-ray Crystallography and Computational Docking for the Detection and Development of Protein–Ligand Interactions
Current Medicinal Chemistry Targeting Nicotinic Receptors for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Subject Index to Volume 5
Current Protein & Peptide Science The Endocannabinoid System and Huntingtons Disease
Current Drug Targets - CNS & Neurological Disorders Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study
Current Drug Targets Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimers Disease
Current Alzheimer Research Pharmacophore and QSAR Modeling of Neuronal Nitric Oxide Synthase Ligands and Subsequent Validation and In Silico Search for New Scaffolds
Medicinal Chemistry Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology Cell Death Targets and Potential Modulators in Alzheimers Disease
Current Pharmaceutical Design





